• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Healthcare costs show signs of moderating

Article

Lincolnshire, Ill.- Healthcare cost increases, while high, are moderating because of decelerating cost trends, according to Hewitt Associates.

Lincolnshire, Ill.- Healthcare cost increases, while high, are moderating because of decelerating cost trends, according to Hewitt Associates.

For 2005, Hewitt is projecting an 11.3% average increase for employers, which is lower than 2004's 12.3% increase.

"While the decelerating cost trend has been going on for almost two years, the data shows this is beginning to show up in premiums," according to Ken Sperling, Hewitt's East region healthcare practice leader. "This should be no surprise to managed care executives."

According to Sperling, the deceleration in underlying cost trend has been driven by a fairly stable physician pricing environment (despite increasing malpractice rates), declines in hospital utilization, and a reduction in the rate of increase of prescription drug costs brought on by patent expirations and movement of certain drugs to OTC status (e.g., Claritin and Prilosec). "In addition, health plan profitability has been healthy, so rate increases do not have to result from a decline in overall loss ratio," he says.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.